Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

OLANZapine-samidorphan

OLANZapine-samidorphan
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Lybalvi TABLET, ORAL 5 mg-10 mg, 10 mg-10 mg, 15 mg-10 mg, 20 mg-10mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

OLANZapine-samidorphan (Lybalvi)

  • 5 mg-10 mg tablet
  • 10 mg-10mg tablet
  • 15 mg-10 mg tablet
  • 20 mg-10 mg tablet

OLANZapine 

  • 5 mg tablet
  • 10 mg tablet
  • 15 mg tablet
  • 20 mg tablet

 

Interchange to OLANZapine monotherapy at the same dosage. Inpatients may use home supply if needed.

 

Reviewed: June 2022 (Lybalvi)

Last updated: Aug. 16, 2022






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved